Figure 6A illustrates the comparative binding pose of curcumin, LY231514 and FdUMP on TS. To confirm that the findings our study is not confined to the TNBC cell line, MDA-MB-231 and will work independent of the receptor status, we evaluated the synergistic effect of the combination in another TNBC cell line, HCC 1937 and triple positive cell line, BT474. The results obtained were in concordance with that obtained in MDA-MB-231 (Figure 6B). Hence, through this study, we propose a novel and effective chemotherapeutic regimen against BCs of all receptor status (Figure 6C). The gene discussed is TYMS; the disease is hepatocellular carcinoma.